Metformin/Remogliflozin etabonate

二甲双胍/瑞格列净

Report date: 2022/01/14 13:23:58

Base Information

Drug NameMetformin/Remogliflozin etabonate
Drug Alias NameRemo-MRemozen-M
ClassificationSmall molecules
Mechanisms of ActionProtein kinase AMP-activated non-catalytic subunit beta 1 activatorsSodium/glucose cotransporter 2 inhibitors
TargetsProtein kinase AMP-activated non-catalytic subunit beta 1Sodium/glucose cotransporter 2
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes Metformin HydrochlorideRemogliflozin etabonate
Global Highest StatusNDA/BLA
Highest Status in ChinaN/A
Originator CompaniesGlenmark Pharmaceuticals Ltd
China Registration ClassN/A

Develop Information

Active CompaniesGlenmark Pharmaceuticals Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A